Amgen (AMGN) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (6.43 million) in Amgen (AMGN). On Thursday, The value of composite uptick trades was $63.47 million, whereas, the value of composite downtick trades was $69.89 million and the ratio between the two was 0.91, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $8.35 million. The negative money flow of ($8.35 million) shows selling on strength. Amgen (AMGN) gained $0.26 intraday at $156.31 and registrered 0.16% for the week.
Amgen (AMGN) : The most positive equity analysts on Amgen (AMGN) expects the shares to touch $195, whereas, the least positive believes that the stock will trade at $157 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $183.75 with an expected fluctuation of $10.37 from the mean. The stock has recorded a 20-day Moving Average of 3.09% and the 50-Day Moving Average is 1.77%.
Amgen (NASDAQ:AMGN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $155.86 and $155.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $156.76. The buying momentum continued till the end and the stock did not give up its gains. It closed at $156.59, notching a gain of 0.35% for the day. The total traded volume was 2,437,062 . The stock had closed at $156.05 on the previous day.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.